Wissenschaftliche Publikationen

Auf dieser Seite finden Sie eine Auswahl wissenschaftlicher Veröffentlichungen zu den Produktkandidaten und Plattformtechnologien der MOLOGEN AG.
Die Publikationen sind nur in englischer Sprache verfügbar.

2018
Immunotherapeutic maintenance treatment with toll-like.receptor 9 agonist lefitolimod in patients with extensive stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study Thomas et. al Annals of Oncology (2018), mdy326 Link
2017
The TLR 9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colonKrarup et. al MucosalImmunology (2017), doi: 10.1038/mi.2017.59Link
TLR9 agonists: Can they exact a toll on HIV persistence?Cyktor et. al Clinical Infectious Diseases (2017), Clin Infect Dis cix2014.Link
Short.course TLR9 agonists treatment impacts innate immunity and plasma viremia in individuals with HIV infectionVibholm, L et al., Clinical Infectious Diseases (2017), Clin Infect Dis cix201.Link
2016
Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural contextKapp, K et al. Immunity, Inflammation and Disease (2016), doi: 10.1002/iid3.126Link
A novel toll-like receptor-9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1 infected autologous CD4+ T cells                Offersen, R et al. Journal of Virology (2016), doi: 10.1128/JVI00222-16Link
Design and characterization of the tumor vaccine MGN1601,allogeneic fourfold gene-modified vaccine cell combined with a TLR-9 agonistVolz, B et al. Molecular Therapy - Oncolytics (2016) 3, 15023; doi:10.1038/mto.2015.23Link
  2015
MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer TherapySchmidt M et al. Gene Therapy of Solid Cancers - Methods in Molecular Biology, Volume 1317, 2015, pp 39-51Link

Sequential chemo-immunotherapy of experimental visceral leishmaniasis using single low dose liposomal amphotericin B and a novel DNA vaccine candidate.

Seifert K et al. Antimicrob. Agents Chemother. 2015 0 (2015), p. AAC. 00273-15v1Link
Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.Mählmann K et al. BMC Veterinary Research 2015, 11:107 doi: 10.1186/s12917-015-0414-9Link
Design and Structural Requirements of the Potent and Safe TLR9 Agonistic       Immunomodulator MGN1703Schmidt M et al.                             Nucleic Acid Therapeutics                     doi:10.1089 / nat.2015.0533Link
Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccineRiede O et al. Gene Therapy advance online publication 30 April 2015; doi: 10.1038/gt.2015.35Link
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside.Wittig B et al.
Critical Reviews in Oncology/Hematology, 2015.
Link
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours.Weihrauch MR et al.Eur J Cancer 51 (2): 146–156, 2015.Link
 
2014
A subgroup of metastatic colorectal cancer patients with very prolonged disease control under maintenance therapy with the TLR-9 agonist MGN1703.J. Riera-Knorrenschild et al.
Ann. Oncol., 25 (suppl. 2): ii8 (abstract PD-0009), 2014.
Link
The randomized phase III IMPALA study: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 in patients with metastatic colorectal cancer carcinoma.D. Cunningham et al.
Ann. Oncol., 25 (suppl. 2): ii98 (abstract PD-0268), 2014.
Link
ASET study: Final results of patients with locally recurrent or metastatic renal cell carcinoma (RCC) treated with MGN1601.V. Grünwald et al.
Ann. Oncol., 25 (suppl. 4): iv366-iv367 (abstract 1063P), 2014.
Link
IMPACT study: A subgroup of metastatic colorectal cancer patients with very prolonged disease control under maintenance therapy with the TLR-9 agonist MGN1703.W. Scheithauer et al.
Ann. Oncol., 25 (suppl. 4): iv366 (abstract 1061P), 2014.
Link
Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 in patients with metastatic colorectal carcinoma - the randomized phase III IMPALA study.D. Arnold et al.
Ann. Oncol., 25 (suppl. 4): iv371 (abstract 1077TiP), 2014.
Link
Cationic Lipid-Formulated DNA Vaccine against Hepatitis B Virus: Immunogenicity
of MIDGE-Th1 Vectors Encoding Small and Large Surface Antigen in Comparison to a Licensed Protein Vaccine
Endmann A et al.
DOI:10.1371/journal.pone.0101715,  July 2014
Link
Genuine Immunomodulation with dSLIM.Kapp K et al.
Molecular Therapy - Nucleic Acids (2014) 3, e170, epub June 24, 2014
Link
IMPACT trial – Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma.Riera-Knorrenschild J
et al.

J Clin Oncol. 32 (suppl.): 5s (abstract: 3615), 2014
Link
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. Schmoll HJ et al.
J Cancer Res Clin Oncol. 140 (9): 1615-1624, 2014
Link
Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: Studies on formulation, biodistribution and vector clearance.Endmann A et al.
Vaccine. 2014; 32(27): 3460-7
Link

Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.Kobelt D et al.
Mol Oncol. 2014; 8(3):609-19
Link
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.Das S et al.
Sci Transl Med. 2014; 6(234): 234-56
Link
Conformation overrides base sequence - insights
from a novel class TLR-9 agonists.
Kapp K et al.
AACR 2014,
abstract no. 2565
Link
ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601.Grünwald V et al.
J Clin Oncol. 32 (4, suppl.): (abstract LBA399), 2014
Link

2013
Updated results of the randomized phase 2 IMPACT trial: Maintenance with TLR-9 agonist MGN1703 vs placebo in patients with metastatic colorectal carcinoma (mCRC).Schmoll HJ et al.
Ann Oncol. 24 (suppl . 4): iv16-iv17 (abstract: O-0012), 2013
Link
Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT).Riera-Knorrenschild J
et al.
J Clin Oncol. 31 (15, suppl 1):  (abstract: 3643), 2013
Link
MGN1703 – structure of agonist determines cellular responses to TLR9 activation.Kapp K et al.
ASGCT 16th Annual Meeting (May 15 – May 18, 2013). (abstract: 686) 2013
Link
Can anthocyanins improve maintenance therapy
of Ph(+) acute lymphoblastic leukaemia?
Köchling J et al.
Eur J Haematol. 2013; 90(4): 291-300
Link
Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601.Grünwald V et al.
J Clin Oncol. 31 (6, suppl.): (abstract 468), 2013
Link

2012
Maintenance treatment with immunomodulator MGN1703 following induction with standard 1st line therapy prolongs progression-free survival in patients with metastatic colorectal (mCRC): results of the phase II/III IMPACT trial.Arnold D et al.
Ann Oncol. 23 (suppl. 9): ix178 (abstract: 518O), 2012
Link
The novel cancer vaccine, consisting of genetically modified allogeneic tumor cells and immunomodulator MGN1601: Updated results of
a phase 1-2 study in patients with advanced renal
cell carcinoma.
Schmidt-Wolf IGH et al.
Ann Oncol. 23 (suppl. 9): ix268 (abstract: 813P), 2012
Link
Prevention and synergistic control of Ph(+) ALL by
a DNA vaccine and 6-mercaptopurine.
Köchling J et al.
Vaccine. 2012; 30(41): 5949-55
Link
Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma.Weikert S et al.
J Clin Oncol. 30 (15, suppl 1): (abstract: 4636), 2012
Link
Intratumoral Dispersion, Retention, Systemic Biodistribution, and Clearance of a Small-Size Tumor Necrosis Factor-a-Expressing MIDGE Vector after Nonviral in Vivo Jet-Injection Gene Transfer. Galling N et al.
Hum Gene Ther Methods. 23: 264-270, 2012
Link
Preliminary Safety Results from the IMPACT Study –
A Phase 2-3 Clinical Study in Patients with Advanced Colorectal Carcincoma with the Immunomodulator MGN1703.
Schmidt M et al.
Mol Ther. 20 (suppl. 1): S262 (abstract: 679), 2012
Link
New Safety and Efficacy Data of a Phase 1-2 Study
in Patients with Advanced Renal Cell Carcinoma, Following Vaccination with Fourfold Gene-Modified, Allogeneic Tumor Cells Combined with a DNA-Based Immunomodulator.
Weikert S et al.
Mol Ther. 20 (suppl 1): S129 (abstract: 327), 2012
Link
Immune-related efficacy data of the phase 1-2 study
of an with fourfold gene-modified allogeneic tumor
cell based vaccine in patients with advanced renal
cell carcinoma.
Weith E et al.
Cancer Res. 72 (8, suppl. 1): (abstract: LB-233), 2012
Link
New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma.Grünwald V et al.
J Clin Oncol. 30 (5, suppl.): (abstract 398), 2012
Link
IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.Tschaika M et al.
Clin Oncol. 30 (4, suppl.): (abstract: 633), 2012
Link

Archiv
Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection.Endmann A et al.
Vaccine. 2010; 28(21): 3642-9
Link
Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia.Köchling J et al.
Vaccine. 2008; 26(36): 4669-75
Link
Minimal size MIDGE vectors improve transgene expression in vivo.Schakowski F et al.
In Vivo. 2007; 21(1):17-23
Link
MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity.Choi Y et al.
Int J Cancer. 2007; 120(9): 1942-50
Link
Effect of different nuclear localization sequences on
the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D.
Zheng C et al.
Vaccine. 2006; 24(21): 4625-9
Link
MIDGE Vectors and dSLIM Immunomodulators: DNA-based Molecules for Gene Therapeutic Strategies, in Modern Biopharmaceuticals.Schmidt M et al.
J. Knäblein and R.H. Müller, Editors. 2005, WILEY-VCH Verlag GmbH&Co. KGaA: Weinheim. 1-29.
DNA immunisation with minimalistic expression constructs.Moreno S et al.
Vaccine. 2004; 22(13-14): 1709-16
Link
Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides.Köchling J et al.
Clin Cancer Res. 2003; 9(8): 3142-9
Link
DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. López-Fuertes L
et al.
Vaccine. 2002; 21(3-4): 247-57
Link
Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide.  Schirmbeck R et al.
J Mol Med (Berl). 2001; 79(5-6): 343-50
Link
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.Wittig B et al.
Hum Gene Ther. 2001; 12(3): 267-78
Link
Form Follows Function, in Plasmid for Therapy and Vaccination.Junghans C et al.
M. Schleef,
Editor 2001, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim. 139-156

Weiterführende Links:

Ansprechpartner:

Dr. Matthias Baumann
research@mologen.com